ASLAN Pharmaceuticals Limited (ASLN)
Stock Price:
$1.71 USD
-0.13 (-7.07%)
Updated Oct 26, 2020 1:04 PM EDT - Market open
Key Info
| Market Cap |
64.96M |
| Revenue (ttm) |
3.00M |
| Net Income (ttm) |
-47.07M |
| Shares Out |
37.99M |
| EPS (ttm) |
-1.24 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$1.71 |
| Previous Close |
$1.84 |
| Change ($) |
-0.13 |
| Change (%) |
-7.07% |
| Day's Open |
1.85 |
| Day's Range |
1.70 - 1.85 |
| Day's Volume |
35,877 |
| 52-Week Range |
0.35 - 8.18 |
More Stats
| Market Cap |
64.96M |
| Enterprise Value |
61.41M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.99M |
| Float |
36.30M |
| EPS (basic) |
-0.29 |
| EPS (diluted) |
-1.24 |
| FCF / Share |
-0.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
239,908 |
| Short Ratio |
2.97 |
| Short % of Float |
0.66% |
| Beta |
2.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
21.65 |
| PB Ratio |
6.05 |
| Revenue |
3.00M |
| Operating Income |
-45.58M |
| Net Income |
-47.07M |
| Free Cash Flow |
-25.51M |
| Net Cash |
3.55M |
| Net Cash / Share |
0.09 |
| Gross Margin |
57,884.51% |
| Operating Margin |
-1,519.30% |
| Profit Margin |
-1,568.90% |
| FCF Margin |
-850.21% |
| ROA |
-41.56% |
| ROE |
-769.78% |
| ROIC |
-430.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.50*
(221.64% upside)
Low
5.00
Current: $1.71
High
6.00
Target: 5.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 3.00 | - | - | 11.55 |
| Gross Profit | 2.59 | - | - | 11.42 |
| Operating Income | -45.58 | -42.35 | -39.14 | -8.70 |
| Net Income | -47.07 | -42.19 | -39.89 | -9.05 |
| Shares Outstanding | 160 | 168 | 168 | - |
| Earnings Per Share | -0.29 | -0.28 | -0.32 | -0.09 |
| Operating Cash Flow | -25.51 | -39.72 | -34.48 | -5.80 |
| Capital Expenditures | - | -23.08 | -0.30 | -0.46 |
| Free Cash Flow | -25.51 | -62.81 | -34.78 | -6.25 |
| Cash & Equivalents | 22.20 | 28.91 | 50.57 | 51.74 |
| Total Debt | 18.65 | 13.97 | 9.68 | 8.34 |
| Net Cash / Debt | 3.55 | 14.93 | 40.89 | 43.40 |
| Assets | 23.35 | 52.88 | 51.33 | 53.71 |
| Liabilities | 23.95 | 22.26 | 15.82 | 12.14 |
| Book Value | -1.68 | 30.62 | 35.51 | 41.57 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ASLAN Pharmaceuticals Limited |
| Country |
Singapore |
| CEO |
Carl Aslan Jason Morton Firth |
Stock Information
| Ticker Symbol |
ASLN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ASLN |
| IPO Date |
May 4, 2018 |
Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.